Manusights vs q.e.d Science: Claim Logic vs Submission Readiness

In our pre-submission review work, we see these products used at different moments for different reasons. We see q.e.d Science pulled in when co-authors are still arguing about what the paper really claims and whether the conclusions follow from the evidence. We see Manusights used when the paper is almost ready and the harder question is whether the finished package can survive editor and reviewer screening.

Our review of the current public materials reinforces that split. q.e.d's strongest public language is about claim trees, evidence logic, originality framing, and private pre-submission use. Manusights is stronger where selective-journal failures actually cluster late in the workflow: citation verification, figure analysis, journal targeting, and escalation to human expert review when AI alone is no longer enough.

q.e.d Science is a "Critical Thinking AI" platform founded by 15+ scientists and technologists from Harvard, Yale, UC Berkeley, Oxford, and Tel Aviv University. It has an official integration with bioRxiv (the preprint server) through the B2X pipeline, and a partnership with Life Science Editors where q.e.d's AI analysis is combined with human editorial judgment at $141.50/hour.

These credentials are strong. The bioRxiv integration means q.e.d has been vetted by one of the most important platforms in scientific publishing. bioRxiv chose q.e.d for its B2X pipeline, calling it a tool that "uses generative AI to analyse the claims and supporting data presented in manuscripts."

The platform is used by scientists at 1,000+ institutions. Dr. Netanella Illouz Eliaz at the Salk Institute describes the feedback as "Nature reviewers-level." Prof. Ryan Flynn at Harvard calls it "exceptionally powerful."

When you submit a manuscript to q.e.d, you receive a "Research Blueprint" within about 30 minutes. The blueprint:

1. Decomposes the paper into individual claims. Every assertion the paper makes is identified and mapped.
2. Maps evidence connections. For each claim, q.e.d shows what evidence supports it and where the logical chain is strong or weak.
3. Identifies gaps. Where the argument has inferential jumps, unsupported conclusions, or claims that don't follow from the evidence, q.e.d flags them with specific solutions - both "possible text amendments" and "alternative experiments."
4. Scores originality. Compares the manuscript against hundreds of similar papers to highlight what is genuinely original and where the novelty claim may be overstated.
5. Generates an overall report. Summary of strengths, weaknesses, and prioritized areas for improvement.

This is a distinctive approach. No other tool decomposes papers into claim trees and maps the logical structure this explicitly. For papers where the argument is genuinely unclear - where co-authors disagree about what the paper is claiming, or where the conclusions leap beyond what the data supports - q.e.d provides unique analytical value.

Based on user feedback and product documentation:

• Inferential jumps. "The data shows X, but the Discussion claims Y" - q.e.d catches these mismatches by mapping claims to evidence explicitly.

• Unsupported conclusions. Claims that sound reasonable but aren't backed by the presented data get flagged with specific suggestions for what additional evidence would be needed.

• Overclaiming. The originality scoring compares your paper against hundreds of similar publications, which helps calibrate whether "we show for the first time" is actually true or whether similar work exists.

• Argument structure. For complex papers with multiple interrelated findings, the claim tree makes the logical structure visible in a way that reading the text linearly doesn't.

A beta tester quoted in The Scientist noted the tool "gave pretty accurate suggestions on what you should do to support your claim." A researcher at Life Science Editors described q.e.d as "a strong first pass" that catches logical issues an editor can then contextualize.

No citation verification against any database. q.e.d compares your paper against similar work to score originality, but it does not check your individual references against CrossRef, PubMed, or arXiv. If reference 14 has a wrong DOI, reference 23 was retracted, or you're missing a competing paper from 3 months ago, q.e.d won't flag it.

The Manusights $49 diagnostic checks every citation against 500M+ papers. At selective journals, a single missing citation to a recent competitor can trigger desk rejection. q.e.d's originality scoring might tell you "similar work exists" - but it won't tell you which specific paper you need to cite.

No vision-based figure analysis. q.e.d analyzes text and claims. It does not read your figures, tables, or supplementary panels. If your Western blot is missing a loading control, your survival curve lacks error bars, or your supplementary figures are incorrectly referenced, q.e.d won't catch it.

For experimental papers, figures are where reviewers spend the most time. A claim tree analysis of the text is valuable, but it misses what reviewers actually look at.

No journal-specific readiness scoring. q.e.d tells you whether the argument is logically sound. It does not tell you whether the paper meets Nature Medicine's editorial bar or whether PNAS would find the scope appropriate. A logically perfect paper can still be desk-rejected for wrong journal targeting.

The Manusights free scan ($0, 1-2 minutes) scores desk-reject risk for your specific target journal. The $49 diagnostic ranks alternatives based on your manuscript content. q.e.d provides no journal-fit assessment at all.

No quantitative readiness score. q.e.d provides qualitative analysis (the claim tree, gap identification, originality scoring against similar papers) but no 0-100 readiness score that tells you where you stand on a submission-readiness continuum.

No human expert escalation within the platform. q.e.d is AI-only. The Life Science Editors partnership adds human editorial judgment at $141.50/hour, but that's a separate vendor relationship. Manusights provides a direct path from Full Review ($49) to named field expert ($1,000+) to CNS editor ($1,500-$2,000) within one platform.

Not all feedback on q.e.d is positive. LabCritics notes that one researcher found suggestions "weren't original" and rated the AI "average." The tool's depth can vary by field - LabCritics specifically notes a "life sciences focus" and that "specialized fields may lack optimal support."

q.e.d itself states that the tool should not be considered "prior publication" and explicitly says it "does not detect fraud or data manipulation" and "assumes data and results are genuine." These are honest and appropriate disclaimers.

Claim-tree decomposition is unique. No other tool provides this level of argument-structure visibility. For papers with complex multi-panel findings, the claim tree shows how pieces connect in a way that reading the text linearly doesn't reveal.

The bioRxiv integration adds credibility and convenience. If you post a preprint on bioRxiv, you can send it directly to q.e.d through the Author Area. This is the only AI review tool with an official bioRxiv pipeline.

Originality scoring against similar papers. By comparing against hundreds of publications, q.e.d helps calibrate novelty claims. This is different from citation verification (checking references) - it's about positioning your work within the landscape.

The Life Science Editors partnership. For researchers who want q.e.d's AI analysis plus human editorial judgment, the LSE partnership provides both. The editor addendum "highlights top reviewer concerns, flags where AI may misread context, and provides big-picture framing and literature positioning." This is a genuine hybrid approach.

Co-author alignment. When co-authors disagree about what the paper is claiming - which happens more often than anyone admits - the claim tree makes the implicit argument structure explicit. This can resolve internal debates before the paper goes to review.

Free access. q.e.d offers access with a work email, no credit card required. The barrier to trying it is very low.

q.e.d and Manusights are genuinely complementary. The strongest workflow:

1. q.e.d first (free, 30 minutes) - stress-test the argument structure and identify logical gaps
2. Fix the argument issues q.e.d identifies
3. manuscript readiness check (1-2 minutes) - check readiness score and desk-reject risk
4. Manusights $49 diagnostic (30 minutes) - verify citations, analyze figures, score journal fit
5. Fix the submission-readiness issues Manusights identifies
6. If career-critical, add Manusights expert review ($1,000+)

Total cost: $49 plus an hour of your time. Total coverage: argument logic (q.e.d) plus citation verification, figure analysis, and journal-fit scoring (Manusights).

Choose q.e.d Science if:

• Your main concern is whether the argument structure and claim-evidence logic hold up
• You want to pressure-test the reasoning before worrying about journal fit or citations
• The paper is still in the conceptual stage where logical coherence matters more than submission readiness

Choose Manusights if:

• You're preparing to submit to a specific journal and need desk-reject risk assessment
• Citations need verification against a live database (q.e.d doesn't verify citations)
• Figures need systematic analysis (q.e.d doesn't analyze figures)
• You need a quantitative readiness score and ranked alternative journals
• The submission is imminent and you need actionable fix priorities

Use both: q.e.d for argument logic early, then manuscript readiness check for submission readiness when you're close to submitting. They catch different problems and complement each other well.